Troglitazone is a potent and selective activator of peroxisome proliferator-activated receptor-γ (PPARγ) with EC50 = 0.55 and 0.78 μM for human and mouse, respectively
Troglitazone does not inhibit PPARα or PPARδ at up to 10 μM (Willson et al.) Troglitazone causes cell cycle arrest at phase G1, inducing caspase-dependent apoptosis in both HeLa and hepatocellular carcinoma cell lines (Yoshizawa et al.; Chang et al.)
